KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

NCT04034823 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

BIOLOGICAL: KN035
BIOLOGICAL: Trastuzumab
DRUG: Docetaxel

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University